Prevnar News and Research

RSS

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

Pfizer’s Prevenar 13 gets US approval for adults

Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus bacteria. The vaccine, which had been approved for children in the United States, is already one of Pfizer's biggest brands and an expanded population of adults could generate more than $1.5 billion in annual sales.

2 Jan 2012

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

31 Dec 2011

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.

31 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. announced today that additional data from several clinical studies of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America, which is being held Oct. 20-23, 2011, in Boston, Mass.

22 Oct 2011

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer Inc. today reported financial results for second-quarter 2011. As a result of Pfizer's decision to sell the Capsugel business, all revenues and expenses related to Capsugel in all periods presented are reflected in a single line, Discontinued operations - net of tax.

3 Aug 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows.

14 Mar 2011

Researchers develop new pneumococcal vaccine through novel discovery approach

Pneumococcus accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge.

17 Feb 2011

Pfizer seeks FDA and EMA approval for expanded use of Prevnar 13 for pneumococcal disease

Pfizer Inc today announced that it has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.

23 Dec 2010

GAVI Alliance launches pneumonia vaccine project in Nicaragua

"A new vaccine against the most deadly forms of pneumonia, one of the world's biggest killers of children, [was] launched in Nicaragua [on Sunday] as part of an effort to prevent 700,000 deaths in poorer countries by 2015," Reuters reports (Kelland, 12/10).

14 Dec 2010

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Pfizer Inc. announced that Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, affordable and accelerated basis to the least developed countries.

13 Dec 2010

Is the decade long flirtation with vaccines over?

In light of increasing competition, saturation of key vaccine sectors and a lack of innovative late-stage vaccine candidates, maintaining the strong growth of the last decade will be a major challenge for the vaccines industry suggests independent market analyst, Datamonitor.

22 Nov 2010